The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel by Pettersen, Alf-Aage R et al.
ORIGINAL CLINICAL INVESTIGATION Open Access
The influence of CYP 2C19*2 polymorphism on
platelet function testing during single antiplatelet
treatment with clopidogrel
Alf-Aage R Pettersen
1*, Harald Arnesen
1,2, Trine B Opstad
1, Ingebjorg Seljeflot
1,2
Abstract
Background: Different platelet function tests can be used to evaluate the degree of achieved platelet inhibition in
patients treated with clopidogrel. The presence of CYP 2C19*2 polymorphism can reduce the formation of the
active metabolite of clopidogrel, resulting in less platelet inhibition.
Patients and Methods: Patients with symptomatic coronary artery disease, all on chronic single aspirin treatment
were randomized to continue on aspirin or change to clopidogrel. In 219 randomly selected clopidogrel treated
patients, platelet reactivity was evaluated by VASP-PRI determination and by use of VerifyNow P2Y12-PRU. The CYP
2C19*2 G/A polymorphism was further determined.
Results: The total frequency of clopidogrel resistance was 29.0% by VASP-PRI and 31.6% by VerifyNow-PRU. The
number of patients being hetero- and homozygous combined for the CYP 2C19*2 polymorphism (GA/AA) was
64 (29%). Platelet reactivity was significantly higher in patients with the polymorphism compared to wild-type
patients (GG). VASP-PRI was 50.9% (SD19) in patients having the polymorphism compared to 38.3% (SD21) in
patients with the GG genotype (p = 0.001). Correspondingly, the mean PRU was 165 (SD67) compared to
124 (SD69) (p < 0.001). The frequency of clopidogrel resistance in patients with the polymorphism was 32%
compared to 16% in wild-type patients when defined by VASP-PRI (p = 0.006). When defined by PRU (VerifyNow),
the corresponding frequencies were 53% and 22% (p < 0.001).
Conclusions: Clopidogrel treated patients with the CYP 2C19*2 polymorphism have significantly increased platelet
reactivity compared to patients with the wild-type, evaluated with the VASP determination, and even more
pronounced with the VerifyNow P2Y12 method.
Trial Registration: ClinicalTrials.gov: NCT00222261
Background
Antiplatelet therapy is widely used in patients with a
high risk of atherothrombosis and has become a corner-
stone in treatment of coronary artery disease (CAD) [1].
Aspirin has been the primary choice for decades,
whereas the benefit of adding clopidogrel in high-risk
patients has been demonstrated in several trials [2,3].
Despite improvement in antiplatelet regimens, patients
on-treatment run a considerable risk for new thrombo-
tic events [4].
Although clinical benefit has been shown with clopi-
dogrel, interindividual variation of platelet inhibition has
been focused as an important explanation of insufficient
platelet inhibition that might be a risk factor for new
thrombotic events. The term “clopidogrel resistance” has
been used to describe this phenomenon [5-7].
The in vivo transformation of clopidogrel to it’s active
metabolite is an important and critical step for the drug’s
antiplatelet effect. Clopidogrel is metabolized to the
active metabolite that inhibits the ADP receptor P2Y12,
and thereby inhibiting the ADP mediated platelet activa-
tion. This metabolization is dependent on the hepatic
cytochrome P450 isoenzymes like CYP2C19, CYP1A2,
CYP2B6, CYP2C9 and CYP3A4. Clopidogrel response
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formation of the active metabolite of the drug [8].
Today, at least 25 single nucleotide polymorphisms
(SNPs) in the gene coding for CYP2C19 have been
described, and the “loss-of-function” allele CYP2C19*2
in exon 5, the most common and most studied poly-
morphism, has been shown to give a significant reduc-
tion in serum concentration of the active metabolite of
clopidogrel and also to reduce inhibition of platelet
aggregation [9-13].
Different platelet function tests have been used to
evaluate the degree of achieved platelet inhibition in
patients treated with clopidogrel. Light transmission
aggregometry with ADP as an agonist, is the most evalu-
ated and used method, but the test is time consuming
and not practical for routine use. A new point-of-care
system is the “VerifyNow” method in which the results
have been shown to predict clinical outcome [14,15].
Determination of “Vasodilator Stimulated Phosphopro-
tein” (VASP) has been considered to be the most speci-
fic test for the degree of inhibition of the platelet P2Y12
receptor. Thus, this test has been considered to give the
best answer on the platelet inhibition achieved by clopi-
dogrel [16,17].
Several studies have reported on the platelet inhibiting
effect of clopidogrel in combination with aspirin by use
of different laboratory methods and cut-off values
[7,18,19]. The aim of the present investigation was to
s t u d yt h ef r e q u e n c yo fr e s i s t a n c et os i n g l ec l o p i d o g r e l
treatment in stable CAD patients by use of both the Veri-
fyNow and the VASP methods. Further, we wanted to
study the influence of the “loss-of-function” polymorph-
ism, CYP2C19*2, on the functional assays.
Materials and methods
Study population
This is a sub-study of the Aspirin and Clopidogrel non-
responsiveness clinical Endpoint Trial (ASCET) in which
patients were enrolled between March 2003 and July
2008 [20]. The ASCET trial is a randomized, single cen-
ter, open labeled clinical trial where 1001 patients with
stable symptomatic CAD, all on chronic aspirin treat-
ment, were randomized to either continued treatment
with aspirin 160 mg/d or to clopidogrel 75 mg/d with a
follow-up for two years. The study was approved by the
regional ethics committee, and patients were included
after giving their written informed consent.
In the present sub-study, all patients randomized to
clopidogrel were consecutively included from October
2005 to June 2008 (n = 219).
In addition, patients from the ASCET cohort being on
aspirin (n = 120), were included to identify the cut-off
level for responsiveness with the VerifyNow- and VASP-
methods. Recording of baseline characteristics were
based on the patients medical files and the medical
interview. Patients were classified as diabetics when pre-
vious diagnosed and treated diabetes or when presenting
with fasting plasma glucose > 7.0 mmol/L. Hypertension
was defined as previous diagnosed and treated hyperten-
sion. Recording of smoking habits were based on patient
interviews. Previous smokers (smoking cessation more
than 3 months ago) were classified as non-smokers.
Current medication and body mass index (BMI) were
recorded by patient interviews and by clinical
examinations.
Blood sampling
One month after randomization to clopidogrel, blood
samples were drawn between 08.00 and 10.30 in fasting
condition 24 hours after the last intake of medication.
Compliance was assessed by interview and by a written
questionnaire. Routine analyses were performed by use
of conventional laboratory methods. Citrated blood
(0.129 mM in dilution 1:10) was used for VASP ana-
lyses, and Vacuette tubes (Grüner Bio-One GmbH,
Austria) (0.109 mM in dilution 1:10) were used for Ver-
ifyNow determination. For gene analyses, EDTA whole
blood was used.
VASP analysis
VASP is an intracellular actin regulatory protein. The
phosphorylation of VASP is regulated by the cyclic ade-
nosine monophosphate cascade. The phosphorylation
status of VASP correlates with P2Y12 receptor inhibi-
tion. Thus, levels of VASP phosphorylation/de-phos-
phorylation reflect P2Y12 inhibition/activation.
VASP was determined, within 48 hours after blood
collection, by use of the PLT VASP/P2Y12 assay (Bio-
cytex, France). The FACS Calibur System (Becton Dick-
inson, Plymouth, UK) was used. The results are
expressed as Platelet Reactivity Index (VASP-PRI) as
described by the manufacturer. The lower the VASP-
PRI, the higher is the biological effect of clopidogrel
[17,21,22]. The intra assay coefficient of variation for
VASP analyses was 2.3%.
VerifyNow-P2Y12
VerifyNow (Accumetrics, San Diego, CA, USA) is an
optically based detection device designed to measure
platelet aggregation. This assay assesses the ability of
activated platelets to bind fibrinogen-coated beads. In
brief, the latter form mixed aggregates with stimulated
platelets in whole blood in a process mediated by plate-
let GPIIb-IIIa receptors. ADP is incorporated to activate
ADP receptors and prostaglandin E1 is added to reduce
the non-specific contribution of the P2Y1 receptor. The
instrument measures the change in light transmittance
and the results are reported in Platelet Reaction Units
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Now analyses was 7%.
Determination of Cut-Off values
We defined the cut-off levels for clopidogrel resistance
as measured by VASP and VerifyNow P2Y12, as the
lower 5 percentile of patients on chronic aspirin treat-
ment (n = 120), giving VASP-PRI ≥55% and PRU ≥170
to be resistant.
DNA isolation
DNA was purified from EDTA whole blood on the
Magna Pure LC Instrument (Roche Diagnostics GmbH,
Mannheim, Germany), using MagNA Pure DNA LC iso-
lation kit, Large Volume (Roche Diagnostics GmbH).
DNA purity and quantity were tested on the NanoDrop,
ND-1000 (Saveen Werner, Sweden) and DNA was kept
at -80°C until analysed.
Genotype analysis
The “loss-of-function” cytochrome 2C19*2 G/A poly-
morphism (rs 4244285) was investigated. Allelic discri-
mination was performed by the ABI Prism 7900 HT
Sequence Detection System using allele specific primers
and probes included in the TaqMan Drug Metabolism
Assay mix (Applied Biosystems, Foster City, CA, USA).
Statistics
Continuous variables are presented as means ± SD and
categorical variables are presented as numbers or per-
centages. Group comparisons were performed by
Student’s unpaired t-tests or Mann-Whitney U-tests
when appropriate for continous variables and by the
chi-square test or Fisher’s exact test for categorical vari-
ables. Correlation analyses were performed by Spear-
mans rho. A p < 0.05 was considered to be statistically
significant. SPSS statistical software, version 18.0 (SPSS
Inc., IBM, Chicago, IL, USA) was used.
Results
In Table 1, some selected clinical and laboratory charac-
teristics of the total population (n = 219), all caucasians,
are given. Number of samples successfully analyzed for
the SNP was 218, 155 for VASP and 212 for VerifyNow,
respectively.
Functional tests
According to the defined cut-off values, the total fre-
quency of clopidogrel resistance was 29% (n = 45) when
measured by VASP determination and 32% (n = 67)
when measured by the VerifyNow P2Y12. The distribu-
tions of response, shown in deciles in the total popula-
tion, are shown in Figures 1a and 1b.
The correlation between the levels of VASP-PRI and
VerifyNow-PRU was highly significant (r = 0.682, p <
0.001) (Figure 2).
Comparing the number of patients being resistant
with the two methods, the concordance (agreement) was
74.5% (p < 0.001, kappa 0.379).
Platelet response as related to genotype
The number of patients being heterozygous (n = 61)
and homozygous (n = 3) combined for the CYP 2C19*2
polymorphism (GA/AA), was 64 (29%). There were no
significant differences in any clinical characteristics
between patients carrying the CYP2C19*2 polymorph-
ism or not, except for a higher frequency of previous
myocardial infarction in patients with the polymorphism
(52% vs 32%, p = 0.004).
Platelet reactivity was significantly higher in patients
with the polymorphism (GA/AA genotypes combined)
compared to wild-type patients (GG) measured by both
methods. Mean VASP-PRI levels were 51% versus 38%,
and mean VerifyNow-PRU levels were 162 vs 121,
respectively (p < 0.001 for both).
Table 1 Baseline Characteristics of the Study Population
Age (years) 62 ± 8.5
Male (%) 79
Caucasian (%) 100
SBP (mmHg) 138.2 ± 18.6
DBP (mmHg) 82.1 ± 9.2
Pulse (beats/min) 61.7 ± 9.3
BMI (kg/m
2) 27.2 ± 3.7
Current smoking (%) 16
History of hypertension (%) 58
Diabetes mellitus (%) 11
Previous PCI (%) 38
Previous MI (%) 37
Previous CABG (%) 19
Total cholesterol (mmol/L) 4.36 ± 0.94
LDL-cholesterol (mmol/L) 2.38 ± 0.83
HDL-cholesterol (mmol/L) 1.34 ± 0.36
Triglycerides (mmol/L) 1.51 ± 1.12
Medication:
Aspirin (%) 100
Clopidogrel (%) 0
Statins (%) 98
Betablockers (%) 71
CCBs (%) 23
PPIs (%) 14
Demographic and clinical characteristics of the study population (n = 219).
Mean values ±SD and proportions are given.
Abbreviations: SBP (systolic blood pressure), DBP (diastolic blood pressure),
BMI (body mass index), PCI (percutaneous coronary intervention), MI
(myocardial infarction), CABG (coronary arterial by-pass grafting), CCBs
(Calcium Channel Blockers), PPIs (proton-pump inhibitors).
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tance in patients with the polymorphism was 46% com-
pared to 22% in wild-type patients when defined by
VASP-PRI (p = 0.003) and 54% compared to 22% when
defined by VerifyNow-PRU (p < 0.001) (Figure 3).
Platelet response in relevant subgroups of patients (Table 2)
In the total population, there were no differences in the
frequency of resistance within relevant subgroups,
including use of medication, when assessed by VASP-
PRI. Evaluated by VerifyNow PRU, higher prevalence of
resistance was found in patients with previous myocardial
infarction (p = 0.006) and in patients with BMI above
median (27 kg/m
2) (p = 0.015). Significantly higher fre-
quency was also observed in calcium-channel blocker
(CCB) users (45% versus 28%, p = 0.031). Specifically, no
differences in the frequency of non-responders were
observed between patients treated with proton pump
inhibitors (PPI) or not (Table 2).
Discussion
I nt h ep r e s e n ts t u d y ,t h em a i nf i n d i n g sw e r et h a t
patients with stable CAD on single clopidogrel treat-
ment carrying the CYP2C19*2 A-allele, had significantly
Figure 1 Frequency distribution (in deciles) of VASP-PRI (Panel a) and VerifyNow-PRU (Panel b) in patients on clopidogrel as single
antiplatelet therapy. Cut-off levels ≥55 and ≥170, respectively, as indicated.
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both the VASP and the VerifyNow methods. The con-
cordance between the functional methods was only fair,
although statistically significant.
We found no differences in the frequencies in demo-
graphic variables in patients having the “loss-of-func-
tion” polymorphism (GA/AA) or not, except for those
presenting with a previous myocardial infarction, which
was significantly more prevalent in patients with the
A-allele. Whether this polymorphism per se increases
the risk for atherothrombosis in clopidogrel-naive
patients remains to be seen.
The presence of the “loss-of function” allele CYP2C19*2
is the most frequent and also the most studied polymorph-
ism among the SNPs in the gene. It is reported that 25-30
percent of the US population is heterozygous while 3-4
percent is homozygous with no corresponding enzymatic
activity, and similar prevalence of the SNP has been
reported in a European population [12,13]. The frequency
of this polymorphism in our study (29%) is in accordance
with these reports.
Even though most of the other SNPs are rare, more
studies are needed to elucidate the role of the less known
polymorphisms of CYP2C19. It has recently been
reported that carriers of CYP2C19*3 A-alleles, in addition
to CYP2C19*2 A-alleles, have an increased risk for acute
stent thrombosis [23]. One study indicates that there
might be ethnical differences, and the “loss-of-function”
CYP2C19*3 A-allele has been reported to be more fre-
quent in an Asian than in US populations [24]. Clopido-
grel treated patients carrying the CYP2C19*2 A-allele
have been shown to have an increased risk for recurrent
ischemic events [16,25,26]. On the contrary, the
CYP2C19*17 has been associated with enhanced expres-
sion and enzymatic activity in the CYP2C19, representing
a “gain-of-function” allele that might increase the risk of
bleeding during clopidogrel treatment [12,27].
Several reports on platelet function testing in patients
on clopidogrel treatment have shown large response
variability and also an association to increased risk for
recurrent ischemic events [4,10,11]. The clopidogrel
response variability is mostly dependent on the extent of
formation of the active metabolite in the hepatic CYP-
system, although other mechanisms like intestinal
absorbtion and platelet turnover may also play a role
[12,28,29].
Determination of clopidogrel resistance as measured
by both VASP-PRI and VerifyNow P2Y12 methods has
been shown to predict clinical outcome [14-17]. How-
ever, there is still a need for standardization on how to
test patients and how to define the cut-off levels. There
are reports using cut-off values from 50 to 70% using
the VASP-PRI method and from 162 to 235 units using
the VerifyNow-PRU. We defined the cut-off values
based on the lower 5 percentile in the ASCET study
population, in which all are CAD patients, while on
aspirin 160 mg/d. With these cut-off levels, we found
that 29% were defined as resistant with the VASP
method and 32% with the VerifyNow P2Y12 method.
This correlates well with previous reports [22,30]. By
using patients with documented CAD to estimate the
cut-off value, we might achieve a lower cut-off value
with a higher number of clopidogrel resistant patients
because the control patients might have more activated
platelets than healthy individuals. Controls from the
same study population might therefore give a relevant
picture.
The correlation between the two tests was highly sig-
nificant, but the agreement between the tests was only
fair (kappa 0.379). Using cut-off values of 70% (VASP-
PRI) and 235 units (VerifyNow-PRU), the frequencies of
Figure 3 The frequencies of clopidogrel resistance in patients
with and without the CYP2C19*2 A-allele, as determined by
VASP-PRI and VerifyNow PRU.
Figure 2 The correlation between platelet reactivity index, PRI,
measured by VASP and platelet reaction unit, PRU, measured
by the VerifyNow.
Pettersen et al. Thrombosis Journal 2011, 9:4
http://www.thrombosisjournal.com/content/9/1/4
Page 5 of 8resistance were reduced (Figure 1). The correlation and
agreement between the methods were, however,
improved (data not shown). Correlation with clinical
end-points will obviously be of great importance for the
evaluation of cut-off values.
Patients carrying the CYP2C19*2 A-allele had signifi-
cantly higher prevalence of clopidogrel resistance mea-
sured by both VASP and VerifyNow. This is in line with
previous reports [9,13]. However, most studies have been
performed with use of only one of the methods and in
patients on dual antiplatelet therapy with clopidogrel and
aspirin. Carrying the polymorphism increases the risk for
a reduced effect of clopidogrel, but it is important to keep
in mind that 22% of the patients without the polymorph-
ism (wild-types) were resistant when determining the pla-
telet function (with both methods) and about 50% of
patients with the polymorphism were responders (54% of
patients with VASP and 46% with VerifyNow). Defining
clopidogrel resistance with the genetic testing alone would
give both a low sensitivity and specificity when identifying
patients resistant to clopidogrel. Routine use of genetic
testing is therefore so far not recommended [31,32]. Even
though genotyping can be used to classify patients as poor
or normal metabolizers, the actual platelet inhibition will
be influenced by several other factors. Drug-drug interac-
tion can alter the metabolization of clopidogrel to its
active metabolite. Interaction with lipophilic statins, PPIs,
calcium-channel blockers and warfarin, which all are
metabolized by the CYP450, can reduce the formation of
the active metabolite of clopidogrel, whereas cilostazol has
been reported to increase the formation of the active
metabolite [33-39]. Diverging results have been reported
on the clinical relevance of the interaction between clopi-
dogrel and PPIs. In our study, the use of PPIs did not
influence the results of the platelet function tests, even in
patients carrying the CYP2C19*2 A-allele. However, the
number of patients using PPIs in our study was relatively
low (n = 31 (14%)).
Patients on calcium-channel-blockers, achieved less
platelet inhibition, with the VerifyNow method, than
patients not treated with calcium channel blockers.
These findings are in accordance with previous reports,
and might be due to CCB inhibition of the cytochrome
P450 3A4 enzyme, giving less formation of active meta-
bolite from clopidogrel [38,40].
High BMI levels have also been shown to contribute to
reduced clopidogrel response with increased platelet aggre-
gation [41]. This is in line with our study, showing that
patients with a BMI above median level had a lower degree
of platelet inhibition compared to patients with BMI lower
than median when measured by VerifyNow. It is not
known whether there are specific mechanisms giving
increased platelet aggregation in patients with a high BMI
or if these findings are mainly a result of potentially con-
founding factors like diabetes, age and the lack of weight-
adjusted maintenance doses of antiplatelet drugs [42,43].
Finally, smoking might induce the CYP450 activation, giv-
ing an increased platelet inhibition from clopidogrel
[44,45]. However, in our study, there were no differences
in platelet inhibition between smokers and non-smokers.
Different results were obtained with the VerifyNow and
VASP methods in relation to differences in sub-groups of
Table 2 Frequencies of clopidogrel resistance in subgroups
VASP-PRI Resistant (n = 45) p-value
1 VerifyNow-PRU Resistant (n = 67) p-value
2
Diabetes Yes 8 (31%) 14 (45%)
No 37 (29%) .831 53 (29%) .079
Smoking Yes 7 (29%) 10 (30%)
No 38 (29%) .987 57 (32%) .861
Hypertension Yes 27 (29%) 42 (35%)
No 18 (29%) 1.000 25 (27%) .262
Previous MI Yes 19 (33%) 34 (43%)
No 26 (27%) .429 33 (25%) .006
Statins Yes 44 (29%) 63 (30%)
No 1 (25%) .857 4 (80%) .180
CCBs Yes 10 (30%) 21 (45%)
No 35 (29%) .856 46 (28%) .031
PPIs Yes 9 (43%) 7 (26%)
No 36 (27%) .440 60 (32%) .665
BMI≥27 (kg/m2) Yes 29 (35%) 43 (39%)
No 16 (22%) .082 24 (24%) .015
Frequencies of clopidogrel resistance in subgroups, evaluated by VASP-PRI (n = 45 of 155) and VerifyNow-PRU (n = 67 of 212). Numbers (proportions) are given.
Abbreviations: MI (myocardial infarction), CCB (calcium channel blockers), PPI (proton pump inhibitors), BMI (body-mass index).
p
1-values refer to differences in subgroups assessed by the VASP-method, and p
2-values refer to differences in subgroups assessed by the VerifyNow-method.
Pettersen et al. Thrombosis Journal 2011, 9:4
http://www.thrombosisjournal.com/content/9/1/4
Page 6 of 8patients. The VerifyNow (P2Y12 cartridge) is measuring
platelet aggregation with ADP as agonist, while VASP
determination is a more direct measure of ADP inhibition
caused by the active metabolite. This is also visualized in
the relatively weak agreement between the methods. It
might be suggested that VerifyNow in a better way express
the platelets total aggregation potential.
T h i sm a yp o s s i b l eb ei nl i n ew i t ho u rf i n d i n go fa n
increased frequency of clopidogrel resistance in patients
with previous MI when tested with the VerifyNow
method.
Conclusions
In the present study, patients with stable CAD on sin-
gle antiplatelet treatment with clopidogrel had signifi-
cantly reduced response when being carriers of the
CYP 2C19*2 variant allele as compared to wild-type
patients, when evaluated with the VASP method, and
even more pronounced with the VerifyNow P2Y12
method. The consequences for clinical outcome are
still debatable.
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